The first priority of therapeutic efficacy of combined BRAF and MEK inhibition also provides the robust cornerstone for future triple combination therapy of BRAF and MEK inhibitors with immunotherapy in patients with MM. This evidence concerns the gene MAP2K7 and Miyoshi myopathy.